Loading...
•
Dec 31, 2020
Matinas BioPharma Q4 2020 Earnings Report
Matinas BioPharma reported financial results for the fourth quarter and full year ended December 31, 2020, along with a corporate update.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $6.6 million, or a net loss of $0.03 per share for the fourth quarter of 2020. The company's cash, cash equivalents and marketable securities were approximately $58.7 million as of December 31, 2020.
Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics.
Enrollment continues in the second patient cohort of the EnACT study of MAT2203 in cryptococcal meningitis, with DSMB evaluation anticipated in Q3 2021.
Collaboration with NIAID to formulate Gilead’s antiviral COVID-19 medication remdesivir has progressed into in vitro studies.
Data from ENHANCE-IT study of LYPDISO™ against Vascepa® supports continued development of LYPDISO; partnership process ongoing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...